180 related articles for article (PubMed ID: 34740039)
1. Mitochondria-targeted Pt(IV) prodrugs conjugated with an aggregation-induced emission luminogen against breast cancer cells by dual modulation of apoptosis and autophagy inhibition.
Su Y; Tu Y; Lin H; Wang MM; Zhang GD; Yang J; Liu HK; Su Z
J Inorg Biochem; 2022 Jan; 226():111653. PubMed ID: 34740039
[TBL] [Abstract][Full Text] [Related]
2. Mitochondria-targeted ruthenium complexes can be generated in vitro and in living cells to target triple-negative breast cancer cells by autophagy inhibition.
Zhang GD; Wang MM; Su Y; Fang H; Xue XL; Liu HK; Su Z
J Inorg Biochem; 2024 Jul; 256():112574. PubMed ID: 38677004
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of Anticancer Action of Novel Imidazole Platinum(II) Complex Conjugated with G2 PAMAM-OH Dendrimer in Breast Cancer Cells.
Czarnomysy R; Muszyńska A; Rok J; Rzepka Z; Bielawski K
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070401
[TBL] [Abstract][Full Text] [Related]
4. Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate.
Qiao X; Gao YY; Zheng LX; Ding XJ; Xu LW; Hu JJ; Gao WZ; Xu JY
Eur J Med Chem; 2021 Nov; 223():113730. PubMed ID: 34388483
[TBL] [Abstract][Full Text] [Related]
5. Cyclometalated iridium(III) complexes as mitochondria-targeted anticancer and antibacterial agents to induce both autophagy and apoptosis.
Chen BB; Pan NL; Liao JX; Huang MY; Jiang DC; Wang JJ; Qiu HJ; Chen JX; Li L; Sun J
J Inorg Biochem; 2021 Jun; 219():111450. PubMed ID: 33826973
[TBL] [Abstract][Full Text] [Related]
6. Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression.
Jin S; Guo Y; Song D; Zhu Z; Zhang Z; Sun Y; Yang T; Guo Z; Wang X
Inorg Chem; 2019 May; 58(9):6507-6516. PubMed ID: 31013065
[TBL] [Abstract][Full Text] [Related]
7. Mitochondria-Specific Anticancer Drug Delivery Based on Reduction-Activated Polyprodrug for Enhancing the Therapeutic Effect of Breast Cancer Chemotherapy.
Wang Y; Zhang T; Hou C; Zu M; Lu Y; Ma X; Jia D; Xue P; Kang Y; Xu Z
ACS Appl Mater Interfaces; 2019 Aug; 11(32):29330-29340. PubMed ID: 31329411
[TBL] [Abstract][Full Text] [Related]
8. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
Huang X; Wang M; Wang C; Hu W; You Q; Yang Y; Yu C; Liao Z; Gou S; Wang H
Bioorg Chem; 2019 Nov; 92():103236. PubMed ID: 31494328
[TBL] [Abstract][Full Text] [Related]
9. Cyclometalated iridium(iii) complexes induce mitochondria-derived paraptotic cell death and inhibit tumor growth in vivo.
He L; Wang KN; Zheng Y; Cao JJ; Zhang MF; Tan CP; Ji LN; Mao ZW
Dalton Trans; 2018 May; 47(20):6942-6953. PubMed ID: 29721561
[TBL] [Abstract][Full Text] [Related]
10. Platinum(IV) complexes conjugated with chalcone analogs as dual targeting anticancer agents: In vitro and in vivo studies.
Huang X; Liu Z; Wang M; Yin X; Wang Y; Dai L; Wang H
Bioorg Chem; 2020 Dec; 105():104430. PubMed ID: 33171407
[TBL] [Abstract][Full Text] [Related]
11. Multiaction Platinum(IV) Prodrug Containing Thymidylate Synthase Inhibitor and Metabolic Modifier against Triple-Negative Breast Cancer.
Muhammad N; Tan CP; Nawaz U; Wang J; Wang FX; Nasreen S; Ji LN; Mao ZW
Inorg Chem; 2020 Sep; 59(17):12632-12642. PubMed ID: 32838518
[TBL] [Abstract][Full Text] [Related]
12. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
[TBL] [Abstract][Full Text] [Related]
13. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
Yang GG; Pan ZY; Zhang DY; Cao Q; Ji LN; Mao ZW
ACS Appl Mater Interfaces; 2020 Sep; 12(39):43444-43455. PubMed ID: 32883070
[TBL] [Abstract][Full Text] [Related]
14. Biotinylated platinum(IV) complexes designed to target cancer cells.
Zhao J; Hua W; Xu G; Gou S
J Inorg Biochem; 2017 Nov; 176():175-180. PubMed ID: 28917640
[TBL] [Abstract][Full Text] [Related]
15. The induction of apoptosis in SGC-7901 cells through the ROS-mediated mitochondrial dysfunction pathway by a Ir(III) complex.
Zhang C; Lai SH; Zeng CC; Tang B; Wan D; Xing DG; Liu YJ
J Biol Inorg Chem; 2016 Dec; 21(8):1047-1060. PubMed ID: 27796592
[TBL] [Abstract][Full Text] [Related]
16. Beyond mere DNA damage: Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands.
Deng Z; Zhu G
Curr Opin Chem Biol; 2023 Jun; 74():102303. PubMed ID: 37075513
[TBL] [Abstract][Full Text] [Related]
17. A targeted theranostic platinum(IV) prodrug containing a luminogen with aggregation-induced emission (AIE) characteristics for in situ monitoring of drug activation.
Yuan Y; Chen Y; Tang BZ; Liu B
Chem Commun (Camb); 2014 Apr; 50(29):3868-70. PubMed ID: 24589580
[TBL] [Abstract][Full Text] [Related]
18. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
[TBL] [Abstract][Full Text] [Related]
19. A Multi-action Pt
Kostrhunova H; Zajac J; Markova L; Brabec V; Kasparkova J
Angew Chem Int Ed Engl; 2020 Nov; 59(47):21157-21162. PubMed ID: 32750194
[TBL] [Abstract][Full Text] [Related]
20. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
Wang Z; Xu Z; Zhu G
Angew Chem Int Ed Engl; 2016 Dec; 55(50):15564-15568. PubMed ID: 27736029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
